{"schema_version":"secwatch.filing_event.v1","accession":"0001974640-26-000001","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.912705+00:00","generated_at":"2026-05-15T22:49:49.219627+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Apogee Therapeutics FY2025 net loss $255.8M; cash $902.9M; zumilokibart milestones","bullets":["Net loss $255.8M (FY2024: $182.1M); R&D expense $214.7M (FY2024: $167.9M).","Cash, equivalents and marketable securities $902.9M; runway into 2H 2028.","APEX Phase 2 Part A 52-week AD data expected March 2026; Part B 16-week data Q2 2026.","Phase 3 AD initiation planned 2H 2026; asthma and EoE trial details later in 2026.","Phase 1b head-to-head APG279 vs DUPIXENT in AD interim data anticipated 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001974640-26-000001","json":"https://secwatch.observer/filing/0001974640-26-000001.json","markdown":"https://secwatch.observer/filing/0001974640-26-000001.md","text":"https://secwatch.observer/filing/0001974640-26-000001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000197464026000001/0001974640-26-000001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000197464026000001/apge-20260302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:49:49.219627+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}